BTG Gains First U.S. Approval With Methotrexate Antidote Voraxaze
Transatlantic specialty pharma BTG adds to its antidote portfolio with FDA approval of Voraxaze, an enzyme drug that breaks down methotrexate in patients whose kidneys are failing due to high serum levels of the chemotherapeutic. BTG also markets snake-bite therapy CroFab and DigiFab for digitalis overdose and recently licensed a late-stage drug to counter toxicity from 5-FU chemotherapy.
More from Archive
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
More from Pink Sheet
It is unclear in a revised staff manual guide whether Commissioner's National Priority Voucher program approval “recommendations” from the drug and biologic center directors will be advisory or decisional, experts told the Pink Sheet.
Revised recommendation is based on most recent data on circulating strains in US, where KP.3 is now dominant. Novavax sticks with plans targeting the JN.1 ‘parent strain.’
Pink Sheet reporter and editors discuss the US FDA’s changes to the COVID-19 vaccine indication and its revocation of the vaccine emergency use authorizations, as well as new vaccine coverage and reimbursement questions.




